Action CLDX CELLDEX THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Temps Différé Nasdaq
Autres places de cotation
 21:57:19 16/07/2024 		Varia. 5j. Varia. 1 janv.
40 USD +1,13 % Graphique intraday de Celldex Therapeutics, Inc. +7,53 % +0,78 %
15:31 Celldex Therapeutics lance des essais de phase 3 pour le barzolvolimab chez des patients souffrant d'inflammation cutanée chronique MT
18/06 CELLDEX THERAPEUTICS, INC. : Stifel Nicolaus persiste à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $525,873, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing
Celldex Therapeutics to Present at Jefferies Healthcare Conference
Celldex Therapeutics Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,319,156, According to a Recent SEC Filing
Celldex Therapeutics Insider Sold Shares Worth $1,298,384, According to a Recent SEC Filing
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024
Certain Common Stock of Celldex Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Certain Stock Options of Celldex Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 29-MAY-2024.
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex: Q1 Earnings Snapshot
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CLDX
  4. Actualités Celldex Therapeutics, Inc.
  5. Autres langues